Pre-procedure desmopressin acetate to reduce bleeding in renal failure: does it really work?

Area of Science:

• Nephrology
• Hematology
• Clinical Pharmacology

Background:

• Desmopressin (DDAVP) is commonly administered to patients with renal failure to prevent bleeding during procedures.
• Evidence supporting the efficacy of DDAVP in this patient population is limited.
• This study aimed to evaluate the clinical practice and outcomes of DDAVP administration in patients undergoing procedures.

Purpose of the Study:

• To assess the practice of using desmopressin (DDAVP) before procedures in patients with renal failure.
• To compare bleeding episodes in patients who received DDAVP versus those who did not.
• To analyze outcomes based on different levels of renal function (GFR).

Main Methods:

• Retrospective review of hospital records for patients undergoing renal biopsy or central line placement (April 2006 - March 2008).
• Patients were stratified into three groups based on Glomerular Filtration Rate (GFR): <15, 15-29, and 30-60 ml/min/1.73 m(2).
• Bleeding events were documented and compared between DDAVP-treated and untreated patients within each GFR category.

Main Results:

• No statistically significant difference in bleeding events was observed between patients who received DDAVP and those who did not, overall and within each GFR group.
• A potential trend suggesting a benefit of DDAVP was noted in patients with the most severe renal impairment (GFR <15 ml/min/1.73 m(2)).

Conclusions:

• The routine use of desmopressin (DDAVP) prior to procedures in patients with renal failure does not appear to significantly reduce bleeding.
• The findings question the current clinical practice of DDAVP administration in this context.
• Patients with severe renal impairment (GFR <15 ml/min/1.73 m(2)) might potentially benefit from DDAVP, warranting further investigation.